Semaglutide

What it is

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural similarity to native human GLP-1. The molecule was developed by Novo Nordisk; brand-name semaglutide was approved by the FDA as Ozempic (2017, type 2 diabetes), Rybelsus (2019, oral form), and Wegovy (2021, chronic weight management). Wegovy received an additional indication in 2024 for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (SELECT trial outcome).

Semaglutide is a 31-amino-acid peptide. Two structural modifications — substitution of alanine at position 8 with α-aminoisobutyric acid, and attachment of a C18 fatty diacid via a γ-glutamic acid spacer at lysine 26 — confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage and promote reversible binding to serum albumin. The combined effect produces a half-life of approximately 165 hours (about one week), enabling once-weekly subcutaneous dosing. The oral formulation pairs semaglutide with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently elevates gastric pH and protects the peptide from proteolysis long enough for absorption across the gastric mucosa.

Mechanism of action

Semaglutide binds the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic β-cells, α-cells, gastric smooth muscle, vagal afferents, and multiple central nervous system regions including the arcuate nucleus, area postrema, and nucleus tractus solitarius.

The downstream effects are coordinated across multiple tissues:

• Pancreatic β-cells: glucose-dependent stimulation of insulin secretion. Crucially, the glucose-dependence of this effect means hypoglycemia risk from semaglutide alone is low — when glucose drops, GLP-1-mediated insulin release shuts off.
• Pancreatic α-cells: suppression of glucagon secretion when glucose is elevated, reducing hepatic gluconeogenesis.
• Gastric smooth muscle: slowed gastric emptying, blunting postprandial glucose excursions and producing prolonged satiety.
• Hypothalamic appetite circuits: direct activation of POMC neurons and indirect inhibition of NPY/AgRP neurons in the arcuate nucleus, reducing appetite and food reward signaling.
• Cardiovascular system: cardiovascular effects are an area of research; Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

Research findings

Semaglutide is among the most extensively studied peptides in modern pharmacology. Key trials:

SUSTAIN program (type 2 diabetes): SUSTAIN 1–7 demonstrated HbA1c reductions of 1.4–1.8% and weight loss of 4–6 kg over 30–56 weeks, exceeding active comparators including sitagliptin, exenatide, and dulaglutide.

STEP program (chronic weight management): STEP 1 (2021, NEJM) randomized 1,961 adults without diabetes to semaglutide 2.4 mg weekly or placebo for 68 weeks. Semaglutide produced mean weight loss of 14.9% vs. 2.4% with placebo. STEP 2 in patients with type 2 diabetes showed 9.6% weight loss. STEP 4 demonstrated that continued treatment maintained weight loss while discontinuation led to substantial regain — important context for patient counseling about expected long-term commitment. Individual results vary.

SELECT trial (cardiovascular outcomes): Published in NEJM 2023, SELECT enrolled 17,604 adults with established cardiovascular disease and BMI ≥27 without diabetes. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72–0.90) over a mean 39.8 months. Exploratory analyses suggested the benefit may not be fully explained by weight loss; the mechanisms are still being studied.

FLOW trial (kidney outcomes): Stopped early for efficacy and published in 2024. Demonstrated reduced progression of diabetic kidney disease and all-cause mortality.

Side effects and contraindications

The most common adverse effects are gastrointestinal: nausea (15–20% of patients during titration), vomiting (5–10%), diarrhea, and constipation. These are dose-related and typically resolve within 4–6 weeks of reaching a stable dose. Slow titration, smaller meals, adequate hydration, and avoiding high-fat meals manage most cases. Persistent vomiting, severe dehydration, or severe abdominal pain warrants reassessment.

Less common but serious:

• Pancreatitis: rare but documented. Personal history of pancreatitis is a relative contraindication.
• Gallbladder events: increased rates of cholelithiasis and cholecystitis, particularly with rapid weight loss. Active gallbladder disease is a contraindication.
• Medullary thyroid carcinoma: rodent studies showed C-cell tumors at supraphysiologic doses; relevance to humans is uncertain but the FDA contraindicates use in patients with personal or family history of medullary thyroid cancer or MEN-2 syndrome.
• Diabetic retinopathy progression: rapid glycemic improvement can transiently worsen retinopathy in patients with established disease — coordination with ophthalmology may be appropriate.

Contraindicated in: pregnancy and breastfeeding, personal/family history of medullary thyroid carcinoma, MEN-2, history of pancreatitis, severe gastrointestinal disease (including gastroparesis).

What we don’t yet know

The very long-term effects of GLP-1 agonist use over decades remain unknown — semaglutide entered widespread use only in the late 2010s. Body composition during weight loss (muscle vs. fat ratio) is an active area of research. Discontinuation typically leads to weight regain, but the trajectory and predictors of regain are still being characterized. Effects on bone density, cognitive function, and addiction-spectrum behaviors are areas of ongoing study.